Topics

Celltrion, Inc. Company Profile

04:16 EST 27th January 2020 | BioPortfolio

Based in Incheon, Republic of Korea, Celltrion, Inc. is a global biopharmaceutical leader with strong research and development capabilities in biosimilar monoclonal antibodies (mAbs) and novel drugs for various therapeutic areas, including oncology and autoimmune diseases. Founded in 2002, Celltrion focuses on promoting the health and welfare of patients in need of innovative biopharmaceutical products through world-class manufacturing and research facilities, developing state-of-the-art technologies, and establishing quality systems. Celltrion’s research and development expertise, coupled with a passion for patient well-being, is a unique set of capabilities that allowed the Company to enter into this highly challenging space.


News Articles [79 Associated News Articles listed on BioPortfolio]

Celltrion sets up Chinese JV and eyes manufacturing facility in country

Celltrion has partnered with Nan Fung Group to create Vcell Healthcare, which will manufacture and commercialize three of Celltrionâs biosimilar products in China.

Celltrion Forms JV with Nan Fung to Develop Three Biosimilars in China

Celltrion of South Korean will form a JV with Nan Fung Group, a Hong Kong investment firm, to develop and commercialize three Celltrion biosimilars in China. The JV, named Vcell Healthcare, will devel...

Celltrion Plans $513 Million Wuhan Biologics Facility; 18 Biologic Launches in China by 2030

Celltrion, a South Korea biopharma, plans to build a $513 million China biologics manufacturing facility in Wuhan. The company said the plant's 120,000 liter capacity will make it the largest facility...

Celltrion's Ambitious Biosimilar Plan: 10 Launches in 10 Years

Celltrion’s chairman Jung Jin Seo announced at last week’s JP Morgan Healthcare Conference the company’s strategy for the next decade.

Celltrion gets EMA nod for subcutaneous infliximab biosimilar

Celltrion receives EMA marketing authorisation for Remsima SC, the first subcutaneously-administered option for delivery of infliximab, a treatment for rheumatoid arthritis.

Celltrion and Juno make biosimilars deal in Australia and Herzuma launches in Iraq

South Korean biotechnology company Celltrion Healthcare (Celltrion) has entered into a partnership with Juno Pharmaceuticals (Juno) to market the trastuzumab biosimilar Herzuma and rituximab biosimila...

Celltrion to spend $514M on biologics plant in China

A total of $514 million over five years has been earmarked by South Korea-based Celltrion for its new biologics plant in Wuha -More- 

Celltrion to launch Temixys double combination once-daily tablet for HIV treatment in US

Celltrion anticipates Temixys to be available in the next coming weeks. Temixys (lamivudine and tenofovir disoproxil fumarate) 300mg/300mg is a once-daily combination of two nucleoside reverse transcr...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis

A new subcutaneous infliximab formulation is being developed by Celltrion, Inc. as an alternative to the intravenous regimen where subcutaneous infliximab injection typically takes less th...

Companies [5 Associated Companies listed on BioPortfolio]

Celltrion Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltr...

Celltrion, Inc.

Based in Incheon, Republic of Korea, Celltrion, Inc. is a global biopharmaceutical leader with strong research and development capabilities in biosimilar monoclonal antibodies (mA...

Celltrion

Celltrion is a biopharmaceutical manufacturing company dedicated to supplying the next generation of biopharmaceutical products to the global community. Our seasoned management team, favorable cost ...

Teva Pharmaceutical Industries Ltd. and Celltrion, Inc.

Celltrion Healthcare

Satellite symposium 3a: Remsima™, the 1st biosimilar monoclonal antibody, Friday 20 February 07:15-08:15

More Information about "Celltrion, Inc." on BioPortfolio

We have published hundreds of Celltrion, Inc. news stories on BioPortfolio along with dozens of Celltrion, Inc. Clinical Trials and PubMed Articles about Celltrion, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celltrion, Inc. Companies in our database. You can also find out about relevant Celltrion, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record